Abstract 978P
Background
The optimal treatment (Tx) strategy for aHCC pts who have progressed on frontline A/B is undefined. We evaluated 2nd line Tx patterns and clinical outcomes of aHCC pts following progression on A/B to identify factors associated with post-progression survival (PPS).
Methods
Real world patient data were retrieved from an international HCC database. PPS was from first radiographic progression on A/B to death. Kaplan-Meier median survivals and 95%CI were compared with univariate Cox-regression analysis. Univariate (UVA) and multivariate (MVA) Cox-regression analyses assessed the impact of baseline clinical factors on PPS.
Results
We identified 406 pts alive with progression on A/B. 220 continued active systemic Tx: 203 received 1 further line, 155 with tyrosine kinase inhibitors (TKIs), 45 with immunotherapy, and the remainder had missing data. Median duration of 2nd line Tx was 2.2 months (mo) (IO: 2.3 mo, TKI; 2.1). Compared to pts who received best supportive care (BSC; n=186), pts on active Tx were younger, Child Pugh class (CP) A , ECOG <2 when A/B stopped, had viral etiology, no extrahepatic disease, and had disease control during A/B. Median follow-up from A/B progression was 7.5 mo (95%CI 6.3-8.6). mPPS for all pts was 6.0 mo (95%CI 5.2-7.2). Continued active Tx was associated with prolonged mPPS compared to BSC (9.7 vs 2.0 mo; HR: 0.30; 95%CI 0.2-0.4, p<0.001). mPPS was longer with IO (11.8 mo; 95%C: 6.4-NA) than with TKIs (8.1 mo; 95%CI 6.3-10.4) or BSC (2.0 mos ;95%CI 1.5-2.9). Male sex, ECOG ≥2 at time of A/B interruption, CP B/C, portal vein tumor thrombosis (PVTT), and primary progression on A/B were associated with increased risk of death in UVA. In MVA, PVTT, ECOG ≥2 and BSC independently predicted poor PPS. Active tx was associated with longer mPPS (8.6 mo, 95%CI 6.3-13.0 vs 2.5, 95%CI 2.1-4.4; HR:0.40, 95%CI 0.28-0.58) after performing propensity score matching for confounding factors (ECOG at A/B stop, PVTT, CPS, DCR during A/B).
Conclusions
In addition to known disease related factors, continuation of systemic Tx instead of BSC following progression on A/B is independently associated with improved PPS in pts with aHCC. mPPS was nearly 1 year with IO-based Tx, suggesting a potential role for IO beyond progression after A/B.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
L. Rimassa: Financial Interests, Personal, Advisory Board, Consulting and advisory role: AstraZeneca, Basilea, Bayer, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, MSD, Nerviano Medical Sciences, Roche, Servier, Taiho Oncology, Zymeworks; Financial Interests, Personal, Invited Speaker, Lecture fees: AstraZeneca, Incyte, Roche, Servier; Financial Interests, Personal, Other, Travel expenses: AstraZeneca; Financial Interests, Institutional, Steering Committee Member: Exelixis, Incyte, Ipsen, Nerviano Medical Sciences, Roche; Financial Interests, Institutional, Coordinating PI, National (Italian) coordinating PI: AstraZeneca, BeiGene; Financial Interests, Institutional, Local PI: Agios, Eisai, Fibrogen, Lilly, MSD, Zymeworks; Financial Interests, Institutional, Funding: Ipsen. A. Vogel: Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Böhringer Mannheim, EISAI, Incyte, Ipsen, Janssen, MSD, PierreFabre, Roche, Servier, Sirtex, Tyra, Tahio; Financial Interests, Personal, Invited Speaker: BMS, Eisai, Incyte, Ipsen, Lilly, MSD, Roche; Financial Interests, Personal, Steering Committee Member: Roche, MSD, BeiGene, Jiangsu Hengrui Medicines.. M. Kudo: Financial Interests, Personal, Invited Speaker: Eisai, Chugai, Eli Liiy, Bayer, Takeda, MSD; Financial Interests, Institutional, Research Grant: Otsuka, Sumitomo Dainippon Pharma, EA Pharma, Taiho, Eisai, AbbVie, Gilead Sciences, Takeda, GE Healthcare, Chugai. S. Ulahannan: Financial Interests, Personal, Advisory Board: array, incyte, bayer, syros, eisai, AstraZeneca; Financial Interests, Institutional, Local PI: AstraZeneca, AbbVie, adlai nortye, arqule, atreca, BI, BMS, Celgene, Ciclomed LLC, Erasca, Evelo Biosciences, Exelexis, G1 Therapeutics, GSK, IGM biosciences, Incyte, isofol, Klus pharma, Macrogenics, merck, Mersana, Oncomed, Pfizer, regeneron, Revolution Medicines, Synermore Biologics, Takeda, Tarveda Therapeutics, Tesaro, Tempest, Vigeo, Tvardi, hutch med. D.J. Pinato: Financial Interests, Personal, Advisory Board: Mina Therapeutics, EISAI, Exact Sciences, MURSLA, H3B, DaVolterra, AstraZeneca, Bayer Healthcare; Financial Interests, Personal, Invited Speaker: BMS, IPSEN, Roche; Financial Interests, Personal, Other, Editor in Chief role: Wiley; Financial Interests, Institutional, Research Grant: BMS, MSD; Non-Financial Interests, Principal Investigator: Incyte, H3B, Starpharma, Roche, Ribon Therapeutics, Turning Point Therapeutics, Apollomics; Non-Financial Interests, Other, Charity Trustee: Cancer Treatment and Research Trust. All other authors have declared no conflicts of interest.
Resources from the same session
967P - The effect of prognosis value of EZH2 (Enhancer Of Zeste Homologue) staining in hepatocellular cancer
Presenter: Mehmet Kidi
Session: Poster session 18
968P - High sensitivity routine blood based detection of HCC: An AI model from 220k patients
Presenter: Kin Nam Kwok
Session: Poster session 18
969P - Establishing a novel routine blood component signature for Hepatocellular Carcinoma (HCC) screening with big clinical data
Presenter: Ka Man Cheung
Session: Poster session 18
970P - Real-world multi-center study of systemic treatment after first-line atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in Asia-Pacific countries
Presenter: Choong-kun Lee
Session: Poster session 18
971P - Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China
Presenter: Zhongqi Fan
Session: Poster session 18
972P - Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in advanced hepatocellular carcinoma
Presenter: Mara Persano
Session: Poster session 18
973P - Clinicopathologic and treatment outcome data in 165 fibrolamellar carcinoma patients
Presenter: Sunyoung Lee
Session: Poster session 18
974P - The barthel index predicts surgical textbook outcomes following hepatectomy for elderly patients with hepatocellular carcinoma: A multicenter cohort study from China
Presenter: Guoyue Lv
Session: Poster session 18
975P - The clinical impact of urinary protein creatinine ratio and AFP at six weeks in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Presenter: Kaoru Tsuchiya
Session: Poster session 18
976P - Overall survival in advanced hepatocellular carcinoma treated with concomitant systemic therapy and stereotactic radiation therapy or systemic therapy alone
Presenter: Alexander Piening
Session: Poster session 18